Clinical Trials Logo

Pancreatic Neoplasms clinical trials

View clinical trials related to Pancreatic Neoplasms.

Filter by:

NCT ID: NCT00593008 Terminated - Clinical trials for Pancreatic Adenocarcinoma

Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

Start date: October 2007
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to try to define the highest doses of temsirolimus and gemcitabine that can be used safely in combination to treat advanced pancreatic cancer. Gemcitabine is a standard chemotherapy used for the treatment of pancreatic cancer.

NCT ID: NCT00587132 Terminated - Pancreatic Cancer Clinical Trials

Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma

Start date: November 2006
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test if secretin-enhanced CT is a useful noninvasive screening tool for pancreatic cancer in a high-risk population.

NCT ID: NCT00574275 Terminated - Pancreatic Neoplasm Clinical Trials

Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer

VANILLA
Start date: December 2007
Phase: Phase 3
Study type: Interventional

The main objective of the study was to evaluate the effectiveness of aflibercept treatment by comparison to placebo in increasing the overall survival (OS) in participants with metastatic pancreatic cancer, treated with gemcitabine. The secondary objectives were to evaluate progression free survival, clinical benefit, overall response, safety and immunogenicity of aflibercept, in the two treatment arms (Arm 1: Aflibercept and Gemcitabine; Arm 2: Placebo and Gemcitabine). The study included an interim analysis of OS. In accordance with the study protocol, an interim analysis was performed for the purpose of futility and overwhelming efficacy. On the basis of the interim analysis, the Data Monitoring Committee (DMC) recommended that this study be terminated for futility based on predefined boundary rules.

NCT ID: NCT00564720 Terminated - Pancreatic Cancer Clinical Trials

Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer

Start date: December 2006
Phase: Phase 2
Study type: Interventional

This randomized phase II trial will compare the efficacy and toxicity of Gemcitabine plus Erlotinib versus Gemcitabine plus Erlotinib plus Oxaliplatin in patients with pancreatic cancer.

NCT ID: NCT00557596 Terminated - Carcinoma Clinical Trials

A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer

Start date: September 2007
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label multicenter, phase 1-2 study. Following determination of the recommended AEG35156 dose in combination with gemcitabine in the initial Phase 1 part of this study, additional patients will be enrolled in the Phase 2 part of the study to assess the activity of the combination first-line in advanced pancreatic cancer.

NCT ID: NCT00553813 Terminated - Pancreatic Cancer Clinical Trials

A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer

Start date: October 2007
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to assess the activity of TPI 287 as single agent therapy for patients with advanced, unresectable pancreatic cancer after failure of gemcitabine-containing therapy. Activity of TPI 287 will be determined by the 6-month survival rate.

NCT ID: NCT00550004 Terminated - Pancreatic Cancer Clinical Trials

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

RP101
Start date: September 2007
Phase: Phase 2
Study type: Interventional

This will be a Phase II, multicenter, randomized, double blind, placebo controlled, study of six 28-day treatment cycles for patients with locally advanced, unresectable, or metastatic pancreatic cancer. The study will be conducted at approximately 55 sites in the North American, Europe, and South America. Approximately 153 subjects will be enrolled in a randomization (ratio 2:1).

NCT ID: NCT00544908 Terminated - Pancreatic Cancer Clinical Trials

Dasatinib in Treating Patients With Stage IV Pancreatic Cancer

Start date: September 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with stage IV pancreatic cancer.

NCT ID: NCT00529113 Terminated - Pancreatic Cancer Clinical Trials

Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer

Start date: September 30, 2007
Phase: Phase 1
Study type: Interventional

This study assesses the safety and efficacy of RTA 402 in combination with gemcitabine in patients with unresectable pancreatic cancer.

NCT ID: NCT00493441 Terminated - Pancreatic Cancer Clinical Trials

AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

Start date: June 2007
Phase: Phase 2
Study type: Interventional

The study was designed to find the optimum AVN944 dose to use in combination with gemcitabine in patients with pancreatic cancer and see if the combination of the 2 drugs was more effective for treating pancreatic cancer than using gemcitabine alone.